Funding Archives

News and Trends 7 Feb 2023

Evonetix closes $24M financing

Evonetix Ltd, a synthetic biology company bringing semiconductor technology to DNA synthesis, has completed a $24 million financing round, extending its total series B funding to over $54 million. This fundraise was led by existing investor Foresite Capital, with Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures and Providence also participating in the round. The […]

February 7, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 7 Feb 2023

Harvard spin-off cellvie closes $5.5M new funding

cellvie Inc., which works on therapeutic mitochondria transplantation (TMT), an approach developed at Harvard Medical School, has closed a $5.5 million financing to get Series A-ready by the end of 2023. Mitochondria dysfunction has been tied to a host of diseases, ranging from neurodegenerative ailments, heart attacks and strokes, to age-related degeneration. “Whilst mitochondria have […]

February 7, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 2 Feb 2023

Recurv Pharma receives funding for cancer therapy development

Recurv Pharma Inc. is receiving up to $24 million in funding from TVM Capital Life Science through its TVM Life Science Innovation II SCSp fund. Recurv Pharma plans to develop a novel taxane therapy to treat solid tumors to the proof-of-concept stage. The U.S. based biotech firm is the eighth early-stage or project-focused company (PFC) […]

February 2, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 24 Jan 2023

Funding for university to develop new motor neuron disease therapies

Medical research charity LifeArc, the Motor Neurone Disease Association (MND Association) and the My Name’5 Doddie Foundation have jointly awarded £1 million ($1.2 million) to researchers at University College London (UCL) to progress two pioneering new therapies that could help transform the lives of those living with motor neuron disease (MND). The research grants are […]

January 24, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 20 Jan 2023

DeuterOncology closes financing round to start lung cancer study

DeuterOncology, a clinical-stage drug development company, has closed €5.65 million ($6.1 million) series A financing, to start the phase I clinical study for its lead product DO-2, an improved MET kinase inhibitor currently being developed as a potential best-in-class targeted therapy for lung cancer. The financing included participation from historical investor Newton Biocapital and new […]

January 20, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 20 Jan 2023

Brenus Pharma and InSphero bag €1.5M for next-generation cancer cell immunotherapy

Brenus Pharma and InSphero AG have received a €1.5 million grant for the collaborative project “STC-1010: A First-in-Class Allogeneic Cell Vaccine Against Cancer,” which aims to use 3D cell culture to develop a novel cell immunotherapy for colorectal cancer. Funding was provided by the Eurostars fund, a support mechanism for small and medium-sized enterprises under […]

January 20, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 19 Jan 2023

Pathalys Pharma brings in $150M for SHPT trials

Pathalys Pharma, Inc. and Launch Therapeutics (Launch Tx) have announced a collaboration to advance phase 3 clinical trials for upacicalcet (designated PLS240 for clinical trials) for the treatment of secondary hyperparathyroidism (SHPT) in patients on hemodialysis. Launch Therapeutics is backed by funds managed by global investment firm Carlyle and its life sciences franchise Abingworth. Pathalys […]

January 19, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 18 Jan 2023

BioInvent receives funding for blood cancer treatments

BioInvent International AB has been selected as partner of The Leukemia & Lymphoma Society’s Therapy Acceleration Program (LLS TAP). The program is aimed at advancing the company’s program to treat blood cancers. The partnership will include access to the scientific, clinical and drug development expertise of LLS as well as a strategic capital equity investment […]

January 18, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 18 Jan 2023

Vésale Bioscience receives €1.8M grant for AMR phage project

Belgian company Vésale Bioscience has received €1.8 million ($1.9 million) in grants from the European Innovation Council (EIC) Accelerator Fund for its PhageDiag project, a phagogram using artificial intelligence that enables decentralized diagnostics and personalized treatment. According to the World Health Organization (WHO), antimicrobial resistance (AMR) is one of the top 10 global public health […]

January 18, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 17 Jan 2023

Multus Biotechnology closes $9.5M funding to bring cultivated meat closer to price parity

Multus Biotechnology Limited, a U.K.-based start-up creating ingredients for the affordable scale-up of cellular agriculture, has completed a £7.9 million ($9.5 million) funding round led by Mandi Ventures. Other investors include SOSV, Big Idea Ventures and SynBioVen, alongside Asahi Kasei, a global company that contributes to a sustainable society by tackling evolving challenges in materials, […]

January 17, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 9 Jan 2023

ExeVir Bio secures funding for COVID program

ExeVir Bio, a Belgian biotech company developing nanobody therapies for broad protection against infectious diseases, has secured a venture debt financing agreement of up to €25 million ($26.5 million) with the European Investment Bank (EIB). The EIB financing will help advance ExeVir Bio’s lead asset, XVR012, into clinical trials for COVID-19. ExeVir Bio’s COVID-19 development […]

January 9, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 9 Jan 2023

ErVaccine raises €4.5M to start therapeutic cancer vaccine trial

ErVaccine Technologies, announces the closing of a €4.5 million ($4.8 million) seed round, including dilutive and non-dilutive funds, with Seventure and Bpifrance as part of the Aide au Développement de l’Innovation (ADI) program. ErVaccine is a biotech company and spin-off from the Centre Léon Bérard-Centre de Recherche en Cancérologie de Lyon, France, which develops next-generation […]

January 9, 2023 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Funding

Evonetix closes $24M financing

Harvard spin-off cellvie closes $5.5M new funding

Recurv Pharma receives funding for cancer therapy development

Funding for university to develop new motor neuron disease therapies

DeuterOncology closes financing round to start lung cancer study

Brenus Pharma and InSphero bag €1.5M for next-generation cancer cell immunotherapy

Pathalys Pharma brings in $150M for SHPT trials

BioInvent receives funding for blood cancer treatments

Vésale Bioscience receives €1.8M grant for AMR phage project

Multus Biotechnology closes $9.5M funding to bring cultivated meat closer to price parity

ExeVir Bio secures funding for COVID program

ErVaccine raises €4.5M to start therapeutic cancer vaccine trial

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!